Compounds · Cagrilintide & amylin analogues · continued

Historical amylin analogues and what happened to them posts 31–37

Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema effect size

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

r.serranoTL213 Jul 2026#31

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

Reading it back, the second half matters more than the first.

11 likes 15d

owen.bradyTL4 Moderator16 Jul 2026 · edited#32

k.farrugia, post #29: Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide. Go to post

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

This is the sort of thing the wiki should carry and currently does not.

4 likes in reply to #29 12d

e.iyerTL218 Jul 2026#33

h.kimani, post #20: Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail. If this contradicts something upthread, the upthread version may well be the better one. Go to post

I read post #31 twice before replying, because I had assumed the opposite.

Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.

A partial answer, offered because a partial answer beats none.

0 likes in reply to #20 10d

ms_hollowayTL4Mass spectrometrist20 Jul 2026#34

Post #31 answers the question as asked. The question underneath it is different.

Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.

25 likes 8d

b.oseiTL222 Jul 2026#35

For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.

7 likes 6d

s.bruunTL225 Jul 2026#36

I changed my mind about historical amylin analogues after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.

1 like in reply to #29 3d

k.dahlbergTL227 Jul 2026#37

Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.

This is the sort of thing that ought to be settled and apparently is not.

0 likes 1d

Suggested topics

Topic	Participants	Replies	Views	Activity
The CagriSema phase 2 paper and what a fixed combination buys — the long version Compounds › Cagrilintide & amylin analogues amylin analogues cagrisema cagrilintide The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about CagriSema phase 2…	+137	158	17k	13mo
Is "synergy" the right word for the combination data? Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Setting out what I think I know about this compound and asking…	+5	9	13k	25d
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial cagrilintide On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue…	+27	31	671	12mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…	+98	105	24k	10mo
Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues effect size cagrilintide Closed On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…		4	19k	11mo

Related topics — sharing the tags randomised trial, cagrilintide, cagrisema

Topic	Participants	Replies	Views	Activity
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Compounds › Oral incretins randomised trial orforglipron PIONEER programme Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Dose…	+48	52	59k	18mo
Primary endpoint hierarchies and why order matters Evidence › Trials randomised trial intention to treat estimand Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about primary endpoint hierarchies in a thread last spring and…		4	308	3mo
Follow-up: Open-label extensions: what survives and what does not Evidence › Trials open label intention to treat surrogate endpoints estimand Solved Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin Open-label extensions down and I want to set…	+22	26	397	16mo
How to read a phase 2 result without treating it as a phase 3 result — what changed since Compounds › Retatrutide TRIUMPH programme randomised trial preprint Solved Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Putting the numbers in the first post, because a question…	+25	35	568	6mo
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? Compounds › Tirzepatide tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about…	+15	19	930	18mo